Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hims & Hers Health ( (HIMS) ) just unveiled an update.
Hims & Hers Health, Inc. reported significant financial growth in the second quarter of 2025, with a 73% increase in revenue year-over-year, reaching $544.8 million. The company also saw a 31% increase in subscribers, totaling over 2.4 million, and a net income of $42.5 million. The company is focusing on expanding its capabilities, including enhancing personalization in pharmacies, expanding lab testing, and growing its international presence, which is expected to further strengthen its market position.
The most recent analyst rating on (HIMS) stock is a Hold with a $40.00 price target. To see the full list of analyst forecasts on Hims & Hers Health stock, see the HIMS Stock Forecast page.
Spark’s Take on HIMS Stock
According to Spark, TipRanks’ AI Analyst, HIMS is a Outperform.
Hims & Hers Health shows significant strengths in financial performance and strategic growth plans, supported by strong earnings call insights. However, the high valuation and technical indicators suggest caution, especially given potential overbought conditions and margin pressures. The overall outlook remains positive but with some risks to consider.
To see Spark’s full report on HIMS stock, click here.
More about Hims & Hers Health
Hims & Hers Health, Inc. is a leading health and wellness platform focused on providing personalized, high-quality care. The company aims to democratize access to precision care and offers solutions that help individuals optimize their health through personalized treatment plans.
Average Trading Volume: 45,968,306
Technical Sentiment Signal: Buy
Current Market Cap: $14B
Learn more about HIMS stock on TipRanks’ Stock Analysis page.